Fig. 4

Depletion of CCR2⁺Ly6C^hi cells enhances adaptive T cell response, which is pivotal for the efficacy of IR + CCR2 ab treatment. a CD8⁺ T cells were purified from draining lymph nodes from WT and CCR2^−/− tumor bearing mice or WT mice that received indicated treatments, and b subjected to ELISPOT assay. c CCR2⁺Ly6c^hi cells were sorted from excised tumors and subjected to suppression assay. Ratio indicates CCR2⁺Ly6c^hi: CD8. d Depleting T cells abolished the therapeutic effect of the IR + anti-CCR2 treatment. e Mice that completely rejected MC38 tumors were re-challenged two months later by five million of MC38 cells in the flanks (n = 5); *P < 0.05; **P < 0.01; ***P < 0.001; Each experiment was repeated three times. Data are presented as mean ± s.e.m